Aethoxysklerol (Polidocanol) is commonly used across domains where additional symptomatic support is needed in managing chronic venous disease. The treatment is generally applied to help address symptoms and improve appearance in relevant clinical contexts.

The medicine is used to manage conditions presenting with systemic or localized discomfort, primarily involving varicose veins, smaller reticular veins, and superficial spider veins (telangiectasias). It is also applied in clinical settings for the supportive management of recurrent or residual varicosities that may reappear following prior procedures.

This approach is relevant for easing symptoms linked to organ-specific functional stress, such as the physical discomfort of heavy, tired, and aching legs, night cramps, and associated localized swelling (oedema). The goal is to support the patient by easing distress and maintaining functional stability during symptomatic periods.

“The treatment is relevant when supportive symptom management is appropriate for remaining symptomatic or visible vessels.”

---

Quick Fact: Relief for Venous Discomfort	Symptom Category	Therapeutic Benefit
Physical Discomfort	Supports relief from chronic aching, heaviness, and leg fatigue.
Visible Veins	Contributes to improving appearance by resolving spider and reticular veins.
Functional Stability	May assist with maintaining comfort and easing symptoms like night cramps.

Who Can and Cannot Use Aethoxysklerol?

Eligibility for Aethoxysklerol (Polidocanol) is strictly determined by official regulatory documents based on a patient's health status and age.

Absolute Contraindications (Must Not Use)

Official labeling mandates that the medicine must not be used by individuals with a known hypersensitivity to Polidocanol or any excipients. It is also absolutely contraindicated in patients with acute thromboembolic diseases (such as Deep Vein Thrombosis) or severe arterial occlusive disease (Fontaine stages III and IV). Individuals who are immobile, have a fever, or have uncontrolled systemic diseases (e.g., severe diabetes) are also excluded.

Age and Special Population Restrictions

Population Category	Regulatory Status
Pediatric Patients (<18)	Safety and effectiveness have not been established.
Older Adults (≥65)	Use is permitted, but insufficient experience exists to assess differential response.
Pregnancy/Lactation	Use is not recommended during pregnancy and should be avoided while breastfeeding.

Restricted Use

Special caution and a thorough risk assessment are required for patients with severe hepatic or renal impairment, or those with a high risk of thrombosis (e.g., known thrombophilia). Use is permitted only if the regulatory-defined treatment benefit clearly outweighs the potential risk.

Interactions with other medicines and products

The official regulatory documents provide specific information regarding the interaction profile of Aethoxysklerol (Lauromacrogol 400), which functions as a local sclerosing agent.

Interaction Category	Official Regulatory Statement
Systemic Drug-Drug Interactions	No formal drug-drug interaction studies have been conducted for Aethoxysklerol. Consequently, no specific concomitant medicines are listed in regulatory documents as pharmacokinetic or pharmacodynamic interactors.
Exposure-Modifying Substances	No other medicinal products are officially listed as altering the plasma exposure (e.g., AUC, Cmax) of Lauromacrogol 400 according to government labeling.
Food, Alcohol, or Supplements	No specific interactions with food, alcohol, supplements, or herbal products are explicitly documented in the official regulatory labels.

---

Interaction-Related Constraints

The constraints on use and administration are derived from mandatory rules documented in the prescribing information:

• Preparation Incompatibility: A mandatory restriction exists against mixing the solution: Aethoxysklerol must not be mixed with any other medicinal products prior to administration. This procedural separation is required due to the absence of compatibility studies.
• Population-Specific Caution: The product is officially not recommended for use in patient populations diagnosed with severe hepatic impairment or severe renal impairment. This restriction relates to the risk of altered clearance capacity, which could affect the overall exposure profile of the active substance.

Overall Interaction Profile: The official interaction structure is primarily defined by the absence of systemic drug interaction data. The regulatory information focuses on essential procedural constraints related to preparation and population-specific restrictions for individuals with compromised clearance, as explicitly stated in the government-approved labeling.

Aethoxysklerol, containing lauromacrogol 400 (polidocanol), acts as a non-ionic detergent with a concentration-dependent effect targeting the vascular endothelium. Its molecules self-aggregate into micelles upon contact with the aqueous environment. These micelles interact directly with the endothelial cell membranes, which are composed of phospholipids and other essential lipid molecules. The interaction type is one of detergent-mediated dissolution of the membrane's lipid and protein components.

This physical interaction causes immediate cytolysis and irreversible structural damage to the endothelial lining. The resulting denudation of the vessel wall initiates a local inflammatory response and subsequent platelet aggregation at the site of injury, followed by the deposition of fibrin and cellular debris. This cascade results in the formation of a thrombus, which serves to occlude the vessel lumen. System-level physiological consequences include the controlled, localized thrombotic occlusion of the targeted vein, which ultimately undergoes replacement by connective, fibrous tissue.

How Aethoxysklerol is Used

Aethoxysklerol (Lauromacrogol 400) is a prescription-only injectable solution used exclusively in a specialized setting. Its administration follows established protocols to ensure proper application.

---

Administration and Dosing

Administration Detail	Standard Instruction
Route of Administration	Strictly Intravascular Injection (IV) for vein treatment. Must not be injected intra-arterially or extravascularly.
Dosing Per Injection	0.1 to 0.3 mL per injection site for spider (≤ 1 mm) and reticular veins (1 to 3 mm). Up to 2 mL for larger varices.
Maximum Per Session	The total volume injected in any single treatment session must not exceed 10 mL.
Dosing Frequency	Treatments are typically performed in multiple sessions, separated by an interval of 1 to 2 weeks.

---

Procedural and Population Rules

Administration requires the patient to be positioned with the targeted limb horizontally or elevated (30–45°). Immediately following the injection session, the patient is required to walk for 15 to 20 minutes.

Proper use is also tied to mandatory post-treatment compression, which must be maintained for a duration that varies by vein size—typically 2 to 3 days for spider veins, or 5 days to 6 weeks for larger varices. Regarding specific populations, the medicine is not recommended for use in children and adolescents.

Research Evidence / Overview of Studies

---

Overall Efficacy and Long-Term Outcomes

Studies have evaluated the drug, which is a sclerosant agent, in research settings focusing on the treatment of varicose veins and other related vascular malformations. Research examined the effect of the treatment on reducing the size and appearance of veins, primarily in the lower limbs. Key endpoints evaluated in this research included:

• Obliteration Rate: Measurement of the successful closure of the targeted vein segments.
• Clinical Severity Score: Assessment of disease progression and symptom burden.
• Recurrence Rate: Monitoring the return of treated venous disease over time.

One key study reported a successful vein obliteration rate ranging from 75% to 90% following treatment, depending on the size and location of the vein.

---

Treatment Modality Research

Research was conducted to evaluate the drug when used in two primary modalities:

• Liquid Sclerotherapy: Involving the direct injection of the liquid formulation into smaller veins (telangiectasias and reticular veins).
• Foam Sclerotherapy: Involving the drug mixed with air or another gas to create a foam, which is typically used for larger varicose veins (great saphenous vein, small saphenous vein). This research examined the foam modality as an alternative to surgical stripping.

Studies comparing foam and liquid modalities often focus on treatment success rates and the volume of drug required. Trials primarily included adults with varying degrees of chronic venous disease.

---

Safety and Tolerability Profiles

Research examined the effects related to administration-site reactions. The most commonly noted adverse effects were minor and localized, including temporary pain, bruising, or hyperpigmentation (darkening of the skin) at the injection site. Serious adverse events, such as deep vein thrombosis (DVT), were rare and typically managed by following specific post-procedure protocols. Studies evaluated the tolerability profile against established safety benchmarks for sclerosing agents.

Common questions about Aethoxysklerol (FAQ)

This section provides general, regulatory-based information and should not be used as a substitute for professional medical advice or consultation regarding your individual health status or treatment plan.

---

Q: How quickly does Aethoxysklerol usually start working?

The mechanism of action, as described in regulatory documents, involves immediate damage to the targeted vein lining, which quickly initiates the process of vessel closure (cytolysis). However, official product information primarily focuses on this biological starting point and does not specify a definite timeline for when a patient will observe the first noticeable clinical improvement or symptom relief.

---

Q: Does Aethoxysklerol cause scarring?

Following successful treatment, the targeted vein undergoes a process where the occluded vessel is eventually replaced by stable connective, fibrous tissue (fibrosis). Official safety information notes that local tissue death (necrosis) is an uncommon side effect, which carries the risk of resulting in a scar.

---

Q: What are the long-term effects of having Aethoxysklerol treatment?

The intended long-term effect is the permanent closure and replacement of the treated vein with fibrous tissue. Studies monitor for the long-term risk of the recurrence of the venous disease. In terms of local appearance, skin discoloration (hyperpigmentation) at the injection site is a common effect, which, in some individuals, has been observed to persist for an extended duration.

---

Q: Is Aethoxysklerol an option for people with a history of blood clots?

Official labeling strictly contraindicates the use of this drug in patients with acute thromboembolic diseases (meaning active blood clots). Special caution and a thorough risk assessment are mandated for individuals who have an established high risk of thrombosis or a known genetic predisposition for clotting disorders.

---

Q: Are there different concentrations of Aethoxysklerol, and why?

Yes, Aethoxysklerol (Polidocanol) is available in different solution concentrations (e.g., 0.5%, 1%, 2%). According to official product information, the different concentrations are required depending on the type and size of the veins being treated. Lower concentrations are generally indicated for very small veins, such as spider veins.

---

Q: What should be done if swelling occurs after an Aethoxysklerol injection?

Swelling (oedema) at the injection site is listed as an uncommon adverse reaction in the product information. Official guidelines emphasize that maintaining the mandated compression bandage or elastic stocking for the prescribed duration is a mandatory part of the post-procedure protocol aimed at managing swelling and minimizing other risks.

---

Q: Is Aethoxysklerol treatment usually painful?

Official adverse reaction data lists temporary injection site pain as a common side effect following the procedure. Furthermore, the active ingredient, Polidocanol, is noted in regulatory documents as having a local anesthetic effect, which may help to mitigate localized sensation during the injection process itself.

---

Q: Is it normal to feel a burning sensation right after the treatment?

Official documentation lists temporary injection site pain as a common adverse reaction that may occur. A specific 'burning' sensation is not listed as a distinct event, but it is a type of localized pain that may be experienced, as pain at the injection site is listed as a common reaction.

---

Q: Can Aethoxysklerol be used if I am taking blood thinners?

No formal drug-drug interaction studies have been conducted for this product, meaning no systemic interactions are officially documented. However, since the drug works by causing controlled thrombosis (blood clotting), the use of blood thinners (anticoagulants) is a factor considered during the required risk assessment, as it could affect the procedure’s intended outcome.

---

Q: Can I drive immediately after a treatment with Aethoxysklerol?

Official post-procedure instructions mandate that the patient must walk for 15 to 30 minutes immediately following the injection session. This requirement for immediate post-procedure activity is a necessary factor in assessing suitability for driving or other forms of travel immediately after the procedure.

---

Q: How long should I wait to exercise after receiving Aethoxysklerol?

Immediate post-procedure guidelines require a period of walking. Furthermore, some official guidelines describe that avoiding heavy exercise and exposure to sources of extreme heat (such as saunas or hot tubs) for several days after the treatment session is part of the precautionary measures.

---

Q: What precautions related to sun exposure are mentioned for Aethoxysklerol?

Official post-procedure advice may recommend that patients avoid sunbathing on the treated limbs for a period of time following treatment. This precaution is related to the drug's common side effect of temporary skin discoloration, or hyperpigmentation, at the injection sites.

---

Q: Can Aethoxysklerol be used by patients with heart conditions?

Official documentation contraindicates the use of the drug in patients with severe arterial occlusive disease. While not a general heart condition, regulatory safety information notes that very rare adverse events include cardiac arrest and stress cardiomyopathy.

---

Q: What steps are usually taken if a patient has an adverse reaction to Aethoxysklerol?

The regulatory documents address severe and serious adverse reactions. For rare but serious events like signs of a stroke or a severe allergic reaction (anaphylaxis), the documents stress the need for immediate medical attention. For accidental injection into an artery, the documented protocol includes attempting to aspirate the solution and injecting a local anesthetic.

---

Q: What should I do if I forget to mention a medicine to my doctor before treatment?

Official regulatory documents explicitly advise that patients inform their doctor of all current and recently taken medicines, including any supplements or herbal products. Although no formal drug-drug interactions are documented, informing the doctor of all current medications is required as part of the complete risk assessment process before the procedure.

---

Q: Is Aethoxysklerol approved for cosmetic use or only medical necessity?

Aethoxysklerol is officially indicated for the sclerotherapy of uncomplicated spider veins and uncomplicated reticular veins of the lower extremities. These indications address both the aesthetic and symptomatic issues often associated with these venous conditions.

---

Q: Is it common for veins to appear worse before they improve after using Aethoxysklerol?

Official documentation describes temporary changes in the treated area. The common adverse reaction list includes bruising and skin discoloration (hyperpigmentation) at the injection site. These common reactions can temporarily make the treated veins look more noticeable before the final therapeutic closure and resolution is observed.

---

Q: Can I travel by airplane right after a treatment?

Regulatory warnings emphasize the need for immediate walking after the procedure and caution against prolonged immobility, which is a recognized risk factor for deep vein thrombosis (DVT). Due to this, caution is required regarding activities, such as long-haul airplane travel, that involve prolonged immobility following the procedure.

---

Q: Is there a maximum number of Aethoxysklerol sessions a person can have?

Official information defines a limit on the total volume that can be injected per treatment session (not to exceed 10 mL). However, the regulatory documents do not specify a lifetime maximum number of treatment sessions an individual may receive.

---

Q: Does Aethoxysklerol contain any latex or rubber?

The regulatory documents provide a full list of excipients (inactive ingredients) in the solution itself, but do not always specify the exact materials used in the ampoule stopper or packaging components. For patients with known sensitivities, assessment of the packaging components prior to use is a required precaution.

Storage and Disposal of Aethoxysklerol

Official regulatory labeling dictates strict conditions for the storage and handling of Aethoxysklerol solution for injection.

Storage Requirements

The product must be stored below 30°C and should not be exposed to excessive heat. It is mandatory that Aethoxysklerol must not be frozen.

To ensure quality, the ampoules must remain in the original container/carton for protection from light. Furthermore, the medicine must be stored out of the sight and reach of children.

Handling and Disposal

Aethoxysklerol is for single use only. Once the ampoule is opened, the solution must be used immediately, and any residual amount must be discarded. The product must also be visually inspected for particulate matter before use.

For disposal, the unused or expired medicine must not be thrown away via wastewater or standard household waste; disposal must adhere to local requirements for medicinal products.